Evidence map›Paper›PMID 34306205›Full record

ArticleExperimental and therapeutic medicine2021

Cell-penetrating heme oxygenase-1 in the therapy of atopic dermatitis in mice.

Fang Tang, Xueqing Ma, Jiayu Sun, Minghui Ru, Tiansheng Qian, Wengjing Ji, Sifan Qian, Hua Li

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fang TangSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Xueqing MaSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Jiayu SunSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Minghui RuSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Tiansheng QianSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Wengjing JiSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Sifan QianSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Hua LiSchool of Medicine, Huzhou University, Huzhou, Zhejiang 313000, P.R. China.
Huzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD), also referred to as atopic eczema, is a long-term inflammatory condition that is characterized by itchy, red, swollen and cracked skin. Accumulating evidence suggests that AD is caused by genetic factors, environmental exposure and immune system dysfunction; however, its underlying molecular mechanism remains unclear. Current treatment strategies aim to decrease the severity and frequency of flares. Heme oxygenase-1 (HO-1) is a nuclear factor erythroid 2-related factor 2 (Nrf2)-regulated gene that plays crucial roles against stress, inflammation and oxidation, and exerts cytoprotective effects. Previous studies have reported that treatment of AD induces high expression levels of HO-1 and Nrf2, indicating that HO-1 may play an important role in the treatment of AD. The present study constructed the recombinant protein, cell-penetrating peptide-HO-1 (CPP-HO-1), which was expressed in

Indexed as

ADcell-penetrating peptidesdinitrochlorobenzeneHO-1recombinant protein

Identifiers

PMID34306205
PMCPMC8281355
OpenAlexW3174942437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.